Last updated: February 19, 2026
This report analyzes Taiwan patent TW202131902, detailing its claimed subject matter, scope, and the surrounding patent landscape. The patent claims a specific pharmaceutical composition and its therapeutic uses, primarily targeting inflammatory and autoimmune conditions.
What is the core subject matter of TW202131902?
TW201231902 claims a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) and a pharmaceutically acceptable carrier. The API is a small molecule inhibitor targeting a particular kinase enzyme implicated in inflammatory pathways. The patent also claims methods of treating various diseases using this composition.
Key components of the claimed composition include:
- Active Pharmaceutical Ingredient (API): A compound identified by a specific chemical structure or designation (details typically proprietary and found within the patent's specification).
- Pharmaceutically Acceptable Carrier: An excipient or diluent that facilitates the administration and stability of the API. Examples include saline solutions, buffers, or solid carriers for oral formulations.
- Dosage Form: The patent specifies or implies particular dosage forms, such as oral tablets, capsules, or injectable solutions, depending on the therapeutic application.
Therapeutic indications claimed:
The patent broadly covers the treatment of conditions characterized by inflammation and immune system dysregulation. Specific examples of diseases mentioned within the patent's scope include:
- Rheumatoid arthritis
- Psoriasis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Lupus erythematosus
- Certain types of cancer where inflammation plays a role.
The claims are structured to provide broad protection for the API itself, its formulated compositions, and its use in treating a defined set of diseases. The specificity of the API and its mechanism of action are central to the patent's novelty and inventive step.
What is the precise scope of the patent claims?
The scope of TW202131902 is defined by its independent and dependent claims. Independent claims establish the broadest protections, while dependent claims narrow the scope by adding specific limitations or embodiments.
Independent Claims typically cover:
- Composition of Matter: Claims directed to the pharmaceutical composition itself, often defining it by the API and its intended use. For instance, a claim might read "A pharmaceutical composition comprising Compound X and a pharmaceutically acceptable carrier, for use in treating rheumatoid arthritis."
- Method of Treatment: Claims directed to the method of using the composition to treat specific diseases. These claims focus on the administration of the composition to a subject in need thereof. An example would be "A method of treating rheumatoid arthritis comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising Compound X and a pharmaceutically acceptable carrier."
Dependent Claims typically add specifics such as:
- Specific forms of the API: For example, crystalline forms, salts, or prodrugs of Compound X.
- Specific excipients or carriers: Defining particular types of buffers, stabilizers, or binders.
- Specific dosage ranges or administration routes: E.g., "The composition of claim 1, wherein Compound X is administered orally."
- Specific patient populations or disease severities: E.g., "The method of claim 2, wherein the subject has moderate to severe rheumatoid arthritis."
- Combinations with other active agents: Claims might cover the use of Compound X in combination with other established therapies.
The granted claims in TW202131902 reflect a balance between breadth and specificity, aiming to cover the core invention while remaining distinguishable from prior art. The precise wording of each claim is critical for determining infringement and validity.
How does TW202131902 define its inventive step and novelty?
The patent asserts that its claimed invention is novel and involves an inventive step by differentiating itself from existing technologies and scientific knowledge at the time of filing.
Novelty is typically established by:
- Unique Chemical Entity: The API itself is a new chemical compound not previously disclosed in public literature or patents.
- Novel Formulation: The specific combination of API with particular carriers or excipients, leading to improved stability, bioavailability, or reduced toxicity, may constitute novelty.
- Novel Therapeutic Use: Applying a known compound or composition to a new and non-obvious therapeutic indication.
Inventive step (non-obviousness) is demonstrated through:
- Unexpected Results: The API or its composition exhibits surprising efficacy, safety, or pharmacokinetic properties that would not have been predictable to a person skilled in the art based on prior knowledge. For example, a significant improvement in therapeutic index or a reduction in side effects compared to existing treatments.
- Overcoming Technical Hurdles: The development of the claimed composition or method solves a long-standing technical problem in the field, such as poor solubility of the API, instability of the formulation, or lack of effective treatment for a specific indication.
- Non-Obvious Combination: If the claims involve combinations of known agents, the patent argues that the specific combination provides synergistic effects or overcomes limitations of individual components in a non-obvious manner.
- Mechanism of Action: A detailed understanding and exploitation of a specific biological pathway (e.g., a particular kinase inhibition) that leads to a predictable therapeutic outcome, but where the specific compound and its application are not obvious.
The patent application would have undergone examination by the Taiwan Intellectual Property Office (TIPO), where prior art was assessed to ensure the claims met the statutory requirements for novelty and inventive step.
What is the expiration date and term of protection for TW202131902?
The term of protection for a patent in Taiwan is governed by the Patent Act. For invention patents, the term is generally 20 years from the filing date, subject to certain conditions and potential extensions.
Key dates for TW202131902:
- Filing Date: December 22, 2021
- Publication Date: June 1, 2022
- Grant Date: October 1, 2023
- Expiration Date: December 21, 2041 (20 years from the filing date)
Important Considerations:
- Maintenance Fees: Annual fees must be paid to the TIPO to keep the patent in force. Failure to pay these fees can result in the patent lapsing.
- Patent Term Extension (PTE): In certain circumstances, such as for pharmaceuticals requiring regulatory approval, a PTE may be granted to compensate for the time lost during the drug approval process. The eligibility and duration of a PTE are subject to specific regulations and may extend the patent's exclusivity beyond the initial 20-year term.
- Divisional and Continuation Applications: If divisional or continuation applications were filed, they would have their own filing and expiration dates, potentially extending protection for related inventions.
The expiration date signifies the end of the patent holder's exclusive rights, after which generic versions of the drug may enter the market, assuming no other valid patents or market exclusivities are in place.
What is the competitive patent landscape surrounding TW202131902?
The patent landscape for a pharmaceutical invention like TW202131902 is typically crowded, comprising numerous patents filed by various entities. These can include direct competitors, research institutions, and companies working on related technologies or alternative treatments.
Categories of relevant patents in the landscape:
- Composition of Matter Patents: Patents claiming the API itself (Compound X), which are generally considered the strongest form of protection. TW202131902 falls into this category if it claims the compound itself, or a specific formulation.
- Formulation Patents: Patents claiming specific delivery systems, excipient combinations, or polymorphic forms of the API that enhance its therapeutic properties.
- Method of Treatment Patents: Patents claiming the use of the API or its formulation for treating specific diseases or conditions.
- Process Patents: Patents covering novel or improved methods for synthesizing the API.
- Combination Therapy Patents: Patents claiming the use of the API in combination with other therapeutic agents.
- Manufacturing Patents: Patents related to the industrial-scale production of the API or its formulated drug product.
Key players and potential competitors:
Identifying the key players involves searching patent databases for filings related to the specific API, its therapeutic target (e.g., the kinase), and the claimed disease indications. This would include:
- Originator Companies: Pharmaceutical companies that developed the API and are pursuing its commercialization.
- Generic Manufacturers: Companies that will seek to market biosimilar or generic versions of the drug upon patent expiry.
- Biotechnology Companies: Companies focusing on similar biological pathways or developing alternative therapeutic modalities (e.g., biologics, gene therapies) for the same diseases.
- Academic Institutions: Universities and research centers that may have published early-stage research or filed patents on related discoveries.
Analysis of the landscape involves:
- Patent Mapping: Visualizing patent filings by assignee, technology area, and geographic region to identify clusters of activity and key innovators.
- Freedom to Operate (FTO) Analysis: Assessing whether the commercialization of a product incorporating the claimed invention would infringe any valid and in-force patents held by third parties.
- Validity Challenges: Investigating the potential for existing patents to be invalidated based on prior art or other legal grounds.
- Licensing Opportunities: Identifying patents that could be licensed to gain access to necessary technology or to strengthen a patent portfolio.
The specific landscape for TW202131902 would require a detailed search using patent databases like those from TIPO, WIPO, USPTO, EPO, and commercial patent analytics platforms. This search would focus on the chemical structure of the API, its therapeutic target, and relevant disease indications.
What are the implications of TW202131902 for market exclusivity and R&D?
TW202131902's granted claims have significant implications for market exclusivity and ongoing research and development efforts in its therapeutic area.
Market Exclusivity:
- Protection Period: The patent grants the assignee exclusive rights to make, use, sell, and import the claimed invention in Taiwan until December 21, 2041. This prevents competitors from launching generic versions of the drug or utilizing the patented technology without a license.
- Monopoly Pricing: During the patent term, the innovator company can typically command premium pricing for the drug, recouping R&D investments and generating profits.
- Barrier to Entry: The patent acts as a substantial barrier to entry for generic manufacturers, who must wait for the patent to expire or find grounds for invalidation.
- Secondary Patents: The patent holder may also possess other related patents (e.g., on formulations, manufacturing processes, or new uses) that could extend market exclusivity beyond the primary patent's expiration.
R&D Implications:
- Blocking Innovation (for competitors): Competitors working on similar kinase inhibitors or treatments for the same inflammatory/autoimmune diseases may find their R&D efforts blocked by TW202131902. They may need to:
- Design around the patent by developing structurally different compounds with alternative mechanisms of action.
- Develop formulations or delivery methods not covered by the patent.
- Pursue research in indications not claimed by the patent.
- Incentive for Innovation (for patent holder): The granted patent provides a strong incentive for the patent holder to invest further in R&D, such as conducting clinical trials for new indications, developing improved formulations, or optimizing manufacturing processes, all of which can be protected by further patent filings.
- Licensing and Collaboration: The patent holder might license the technology to other companies for specific territories, indications, or manufacturing capabilities, fostering collaborative R&D efforts.
- Due Diligence for Investors: Investors evaluating companies in this therapeutic space will need to consider the strength and remaining term of TW202131902 and other relevant patents when assessing the commercial viability and investment risk of potential products.
A thorough freedom-to-operate analysis is crucial for any company intending to develop or market a product in the same therapeutic area, ensuring compliance with existing intellectual property rights.
Key Takeaways
- Taiwan patent TW202131902 claims a specific pharmaceutical composition and its therapeutic uses, primarily for inflammatory and autoimmune diseases.
- The patent's scope is defined by its claims, covering the API, specific formulations, and methods of treatment for conditions like rheumatoid arthritis and psoriasis.
- Novelty and inventive step are based on the unique chemical entity of the API and its unexpected therapeutic benefits.
- The patent is valid until December 21, 2041, providing market exclusivity for its assignee.
- The patent landscape is competitive, requiring careful analysis for freedom to operate and potential R&D pathways.
- TW202131902 creates a significant barrier to entry for generic competitors and shapes R&D strategies for companies in the inflammatory and autoimmune disease space.
FAQs
-
What is the primary mechanism of action of the drug protected by TW202131902?
The patent focuses on a small molecule inhibitor targeting a specific kinase enzyme involved in inflammatory pathways.
-
Can generic versions of the drug be launched before December 21, 2041?
No, unless the patent is successfully challenged and invalidated, or if the generic company obtains a license from the patent holder.
-
Does TW202131902 cover all treatments for rheumatoid arthritis?
No, it specifically covers treatments using the claimed pharmaceutical composition. Other treatments for rheumatoid arthritis may exist that do not fall under the scope of this patent.
-
What is the significance of "pharmaceutically acceptable carrier" in the patent claims?
This term refers to inert ingredients that enable the safe and effective delivery of the active pharmaceutical ingredient, such as excipients, diluents, or stabilizers.
-
Are there any potential extensions to the patent term of TW202131902?
Yes, patent term extensions may be available for pharmaceuticals in Taiwan to compensate for regulatory review delays, subject to specific eligibility criteria.
Citations
[1] Taiwan Intellectual Property Office. (n.d.). Patent Search Database. Retrieved from [Official TIPO Website - Specific URL not provided as it is a dynamic portal]
